Literature DB >> 4045880

Endocrine treatment of prostatic cancer.

G Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4045880      PMCID： PMC1289941          DOI： 10.1177/014107688507801001

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  19 in total

1.  Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen.

Authors:  C Huggins; W W Scott
Journal:  Ann Surg       Date:  1945-12       Impact factor: 12.969

2.  Predicting the response of prostatic carcinoma to endocrine therapy.

Authors:  R Ghanadian; G Auf; G Williams; A Davis; B Richards
Journal:  Lancet       Date:  1981 Dec 19-26       Impact factor: 79.321

Review 3.  The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review.

Authors:  C E Blackard
Journal:  Cancer Chemother Rep       Date:  1975 Jan-Feb

4.  Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer.

Authors:  A Coune; P Smith
Journal:  Cancer Chemother Rep       Date:  1975 Jan-Feb

5.  Analysis of androgen receptors in the human prostate by isoelectric focussing in polyacrylamide gel.

Authors:  G Auf; R Ghanadian
Journal:  J Steroid Biochem       Date:  1981-12       Impact factor: 4.292

6.  Steroid receptors and hormone responsiveness of human prostatic carcinoma.

Authors:  G Concolino; A Marocchi; G Margiotta; C Conti; F Di Silverio; R Tenaglia; F Ferraro; U Bracci
Journal:  Prostate       Date:  1982       Impact factor: 4.104

7.  Physiologic basis for hormonal theapy in carcinoma of the prostate.

Authors:  P C Walsh
Journal:  Urol Clin North Am       Date:  1975-02       Impact factor: 2.241

8.  Anti-estrogens in the treatment of prostatic cancer.

Authors:  L Denis; G Declercq
Journal:  Acta Urol Belg       Date:  1980-01

9.  Long-term survival after hormonal therapy for stage D prostatic cancer.

Authors:  W G Reiner; W W Scott; J C Eggleston; P C Walsh
Journal:  J Urol       Date:  1979-08       Impact factor: 7.450

10.  The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.

Authors:  J Trachtenberg
Journal:  J Urol       Date:  1983-06       Impact factor: 7.450
View more
  1 in total

1.  A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).

Authors:  S N Freeman; W I Mainwaring; B J Furr
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.